The High Dose Aflibercept DME Trial
18m
·
Retina Synthesis
·
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
The episode The High Dose Aflibercept DME Trial from the podcast Retina Synthesis has a duration of
18:43. It was first published
More episodes from Retina Synthesis
The GALE Extension Study
We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates
AXPAXLI for Diabetic Retinopathy
We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.
NSAIDS in the treatment of Central Serous Chorioretinopathy
We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas
EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD
We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.
Intravitreal Gene Therapy for neovascular AMD with 4D-150
We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.